Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amitriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 8/20 | 1.00 |
| ▸ | HTR2B | P41595 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 6/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitriptyline SCHEMBL7824 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL29359365 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL28299765 | 0.98 | SLC6A2 (0.97) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL41079 | 0.98 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL7215255 | 0.98 | SLC6A2 (0.97) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL29356807 | 0.98 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL14937172 | 0.98 | SLC6A2 (1.00) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL3055149 | 0.97 | SLC6A2 (0.94) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL14918734 | 0.97 | SLC6A2 (0.97) | SLC6A2HRH1HTR2BKCNH2CHRM2 | |
| Amitriptyline SCHEMBL7214653 | 0.91 | SLC6A2 (0.83) | SLC6A2HRH1HTR2BKCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024032611-A1 | LIPID COMPOSITION | 斯微(上海)生物科技股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| WO-2023246218-A1 | IONIZABLE LIPID FOR NUCLEIC ACID DELIVERY AND COMPOSITION THEREOF | 成都威斯津生物医药科技有限公司 | 2023-12-28 | — | — | WO | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3615014-A1 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | Algotherapeutix (FR) | 2020-03-04 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2659913-B1 | Method to identify p11 modulators | UNIV ROCKEFELLER (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20150071858-A1 | NOVEL THERAPEUTIC AND DIAGNOSTIC PRODUCTS AND METHODS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-03-12 | — | — | US | disclosed |
| US-20130330740-A1 | NOVEL THERAPEUTIC AND DIAGNOSTIC PRODUCTS AND METHODS | THE ROCKEFELLER UNIVERSITY (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2659913-A2 | Method to identify p11 modulators | The Rockefeller University (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8470548-B2 | Diagnosis of depression | INTRA-CELLULAR THERAPIES, INC. | 2013-06-25 | — | — | US | disclosed |
| EP-2026845-A2 | NOVEL THERAPEUTIC AND DIAGNOSTIC PRODUCTS AND METHODS | THE ROCKEFELLER UNIVERSITY (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1976495-A2 | COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER | Aarhus Universitet (DK) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007146372-A2 | NOVEL THERAPEUTIC AND DIAGNOSTIC PRODUCTS AND METHODS | THE ROCKEFELLER UNIVERSITY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007076875-A2 | COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER | AARHUS UNIVERSITET (DK) | 2007-07-12 | — | — | WO | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005112911-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-4753938-A | ANTIDEPRESSANTS, ANTIARRHYTHMIA AGENTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1988-06-28 | — | — | US | disclosed |
| US-4602018-A | ANTIDEPRESSANTS, ANTIARRHYTHMICS | EGYT GYOGYSZEVEGYESZETI GYAR (HU) | 1986-07-22 | — | — | US | disclosed |